| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Histiocytosis, Langerhans-Cell | 77 | 2025 | 241 | 13.970 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 25 | 2021 | 149 | 6.060 |
Why?
|
| Proto-Oncogene Proteins B-raf | 18 | 2025 | 222 | 3.010 |
Why?
|
| Erdheim-Chester Disease | 9 | 2025 | 28 | 2.470 |
Why?
|
| Histiocytosis, Sinus | 10 | 2024 | 34 | 2.450 |
Why?
|
| Xanthogranuloma, Juvenile | 6 | 2022 | 34 | 1.830 |
Why?
|
| Mutation | 20 | 2024 | 6250 | 1.210 |
Why?
|
| Autoimmune Lymphoproliferative Syndrome | 3 | 2020 | 6 | 1.200 |
Why?
|
| Herpesvirus 4, Human | 32 | 2021 | 673 | 1.160 |
Why?
|
| Macrophage Activation Syndrome | 3 | 2018 | 11 | 1.130 |
Why?
|
| Neurodegenerative Diseases | 5 | 2025 | 281 | 1.100 |
Why?
|
| Epstein-Barr Virus Infections | 5 | 2020 | 292 | 0.990 |
Why?
|
| Humans | 189 | 2025 | 132247 | 0.930 |
Why?
|
| Histiocytosis | 4 | 2020 | 19 | 0.880 |
Why?
|
| Child, Preschool | 66 | 2025 | 14736 | 0.860 |
Why?
|
| Infant | 53 | 2025 | 13049 | 0.850 |
Why?
|
| Tumor Necrosis Factor-alpha | 5 | 2018 | 666 | 0.850 |
Why?
|
| Cytarabine | 7 | 2023 | 102 | 0.830 |
Why?
|
| Child | 92 | 2025 | 25783 | 0.810 |
Why?
|
| Ferritins | 5 | 2018 | 109 | 0.760 |
Why?
|
| Langerhans Cells | 4 | 2021 | 21 | 0.700 |
Why?
|
| Central Nervous System Diseases | 3 | 2010 | 109 | 0.670 |
Why?
|
| Male | 101 | 2025 | 65012 | 0.640 |
Why?
|
| Lymphoproliferative Disorders | 10 | 2021 | 225 | 0.630 |
Why?
|
| Adolescent | 57 | 2025 | 20557 | 0.620 |
Why?
|
| Pneumothorax | 1 | 2020 | 83 | 0.620 |
Why?
|
| Rituximab | 2 | 2018 | 167 | 0.610 |
Why?
|
| Female | 100 | 2025 | 70785 | 0.600 |
Why?
|
| Lung Diseases | 3 | 2020 | 408 | 0.600 |
Why?
|
| Etanercept | 1 | 2018 | 47 | 0.590 |
Why?
|
| Parvovirus B19, Human | 6 | 2009 | 31 | 0.590 |
Why?
|
| Biological Products | 1 | 2020 | 137 | 0.570 |
Why?
|
| Vinblastine | 7 | 2014 | 57 | 0.560 |
Why?
|
| Bone Marrow | 15 | 2020 | 327 | 0.560 |
Why?
|
| Osteopontin | 1 | 2018 | 52 | 0.560 |
Why?
|
| Interleukin-18 | 1 | 2018 | 68 | 0.550 |
Why?
|
| Lymphocytes | 4 | 2015 | 364 | 0.550 |
Why?
|
| MAP Kinase Signaling System | 6 | 2024 | 309 | 0.540 |
Why?
|
| Adult | 45 | 2025 | 31614 | 0.530 |
Why?
|
| Protein Kinase Inhibitors | 5 | 2024 | 608 | 0.520 |
Why?
|
| Mannose-Binding Lectins | 6 | 2020 | 26 | 0.510 |
Why?
|
| Dendritic Cells | 11 | 2020 | 448 | 0.510 |
Why?
|
| Lectins, C-Type | 6 | 2020 | 72 | 0.500 |
Why?
|
| Hydroxyurea | 1 | 2016 | 84 | 0.480 |
Why?
|
| Leukocytes, Mononuclear | 3 | 2025 | 356 | 0.480 |
Why?
|
| Skin Neoplasms | 2 | 2023 | 897 | 0.470 |
Why?
|
| Parvoviridae Infections | 5 | 2009 | 37 | 0.470 |
Why?
|
| Diagnosis, Differential | 10 | 2025 | 1966 | 0.470 |
Why?
|
| Immunosuppressive Agents | 4 | 2017 | 673 | 0.470 |
Why?
|
| Antigens, CD | 6 | 2020 | 436 | 0.470 |
Why?
|
| Antineoplastic Agents | 4 | 2020 | 1829 | 0.450 |
Why?
|
| fas Receptor | 2 | 2014 | 47 | 0.450 |
Why?
|
| Pore Forming Cytotoxic Proteins | 1 | 2014 | 19 | 0.450 |
Why?
|
| Lysosomal-Associated Membrane Protein 1 | 1 | 2014 | 10 | 0.450 |
Why?
|
| Fluorodeoxyglucose F18 | 4 | 2019 | 134 | 0.440 |
Why?
|
| Positron-Emission Tomography | 4 | 2013 | 311 | 0.440 |
Why?
|
| Hodgkin Disease | 7 | 2016 | 304 | 0.440 |
Why?
|
| Nervous System Diseases | 1 | 2018 | 412 | 0.440 |
Why?
|
| Cell Degranulation | 1 | 2014 | 29 | 0.440 |
Why?
|
| Bone Diseases | 3 | 2012 | 46 | 0.440 |
Why?
|
| Remission Induction | 8 | 2023 | 306 | 0.430 |
Why?
|
| Epistasis, Genetic | 1 | 2014 | 102 | 0.430 |
Why?
|
| Vincristine | 6 | 2010 | 196 | 0.420 |
Why?
|
| DNA, Viral | 15 | 2002 | 492 | 0.410 |
Why?
|
| Polymerase Chain Reaction | 17 | 2009 | 1555 | 0.390 |
Why?
|
| Histiocytosis, Non-Langerhans-Cell | 4 | 2003 | 15 | 0.390 |
Why?
|
| Mercaptopurine | 4 | 2013 | 72 | 0.390 |
Why?
|
| Methotrexate | 5 | 2013 | 351 | 0.370 |
Why?
|
| Histiocytes | 6 | 2018 | 24 | 0.370 |
Why?
|
| Interleukin-17 | 2 | 2011 | 129 | 0.370 |
Why?
|
| Prednisone | 8 | 2014 | 253 | 0.370 |
Why?
|
| Magnetic Resonance Imaging | 11 | 2023 | 3853 | 0.360 |
Why?
|
| Disease Management | 5 | 2020 | 565 | 0.360 |
Why?
|
| Bone and Bones | 3 | 2014 | 301 | 0.360 |
Why?
|
| Lymphoma, AIDS-Related | 7 | 2003 | 35 | 0.360 |
Why?
|
| Models, Genetic | 1 | 2014 | 771 | 0.350 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 11 | 2024 | 1348 | 0.350 |
Why?
|
| Immune System Diseases | 1 | 2011 | 52 | 0.340 |
Why?
|
| Autoimmune Diseases | 3 | 2020 | 273 | 0.330 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 6 | 2023 | 1192 | 0.330 |
Why?
|
| Cyclosporine | 2 | 2017 | 126 | 0.330 |
Why?
|
| Infant, Newborn | 16 | 2020 | 8548 | 0.330 |
Why?
|
| Antibodies, Monoclonal, Humanized | 4 | 2023 | 559 | 0.320 |
Why?
|
| Hematologic Neoplasms | 4 | 2017 | 294 | 0.320 |
Why?
|
| Epidermis | 1 | 2010 | 64 | 0.320 |
Why?
|
| Thalidomide | 2 | 2007 | 40 | 0.320 |
Why?
|
| Brain Neoplasms | 2 | 2022 | 1410 | 0.310 |
Why?
|
| Skin Diseases | 5 | 2015 | 136 | 0.310 |
Why?
|
| Lymphoma, B-Cell | 3 | 2013 | 148 | 0.300 |
Why?
|
| Predictive Value of Tests | 3 | 2014 | 2314 | 0.290 |
Why?
|
| Acquired Immunodeficiency Syndrome | 5 | 2000 | 236 | 0.280 |
Why?
|
| Clinical Trials as Topic | 5 | 2020 | 1161 | 0.280 |
Why?
|
| Polymorphism, Genetic | 3 | 2003 | 803 | 0.280 |
Why?
|
| Myeloid Cells | 4 | 2023 | 117 | 0.280 |
Why?
|
| Promoter Regions, Genetic | 3 | 2007 | 1284 | 0.280 |
Why?
|
| Adenine Nucleotides | 3 | 2024 | 36 | 0.270 |
Why?
|
| Arabinonucleosides | 3 | 2024 | 33 | 0.270 |
Why?
|
| Hematopoietic Stem Cells | 5 | 2021 | 551 | 0.270 |
Why?
|
| Immunotherapy | 2 | 2018 | 749 | 0.270 |
Why?
|
| Recurrence | 10 | 2024 | 1453 | 0.260 |
Why?
|
| Lymph Nodes | 8 | 2020 | 389 | 0.260 |
Why?
|
| Hydrocephalus | 1 | 2010 | 277 | 0.260 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 4 | 2014 | 146 | 0.260 |
Why?
|
| Erythema Infectiosum | 3 | 1996 | 8 | 0.260 |
Why?
|
| Sepsis | 3 | 2021 | 516 | 0.250 |
Why?
|
| Leiomyosarcoma | 6 | 2003 | 29 | 0.250 |
Why?
|
| Herpesviridae Infections | 9 | 2000 | 146 | 0.250 |
Why?
|
| Purpura, Thrombocytopenic, Idiopathic | 3 | 1996 | 54 | 0.240 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2008 | 153 | 0.240 |
Why?
|
| Granuloma, Plasma Cell | 1 | 2005 | 6 | 0.240 |
Why?
|
| Brain Diseases | 2 | 2005 | 308 | 0.240 |
Why?
|
| Antimetabolites | 1 | 2005 | 30 | 0.240 |
Why?
|
| Burkitt Lymphoma | 4 | 2013 | 141 | 0.240 |
Why?
|
| Prognosis | 11 | 2020 | 5016 | 0.240 |
Why?
|
| Disease-Free Survival | 6 | 2016 | 956 | 0.230 |
Why?
|
| Neoplasms | 9 | 2019 | 2961 | 0.230 |
Why?
|
| Castleman Disease | 2 | 2004 | 16 | 0.230 |
Why?
|
| Gene Expression Profiling | 2 | 2010 | 1883 | 0.230 |
Why?
|
| Endocrine System Diseases | 1 | 2025 | 43 | 0.230 |
Why?
|
| Lymphoma, Non-Hodgkin | 5 | 2016 | 169 | 0.230 |
Why?
|
| Bone Marrow Transplantation | 6 | 2010 | 611 | 0.220 |
Why?
|
| Inflammation | 3 | 2021 | 1522 | 0.220 |
Why?
|
| Salvage Therapy | 3 | 2024 | 200 | 0.220 |
Why?
|
| Biomarkers | 6 | 2020 | 3404 | 0.220 |
Why?
|
| Cell Differentiation | 5 | 2023 | 1965 | 0.220 |
Why?
|
| Drug Therapy, Combination | 7 | 2014 | 1177 | 0.220 |
Why?
|
| HLA-C Antigens | 1 | 2003 | 7 | 0.210 |
Why?
|
| HLA-DR4 Antigen | 1 | 2003 | 6 | 0.210 |
Why?
|
| Retrospective Studies | 16 | 2022 | 17395 | 0.210 |
Why?
|
| Biopsy | 6 | 2018 | 1288 | 0.210 |
Why?
|
| Gene Expression Regulation, Viral | 2 | 1997 | 130 | 0.210 |
Why?
|
| Genes, Viral | 9 | 1998 | 181 | 0.200 |
Why?
|
| Middle Aged | 16 | 2025 | 29021 | 0.200 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2005 | 305 | 0.200 |
Why?
|
| Immunocompromised Host | 2 | 2019 | 308 | 0.190 |
Why?
|
| Tumor Virus Infections | 5 | 1999 | 140 | 0.190 |
Why?
|
| Immunologic Deficiency Syndromes | 3 | 1997 | 216 | 0.190 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2022 | 65 | 0.180 |
Why?
|
| Central Nervous System | 2 | 2003 | 283 | 0.180 |
Why?
|
| Phenotype | 5 | 2019 | 4540 | 0.180 |
Why?
|
| Germ-Line Mutation | 3 | 2022 | 368 | 0.170 |
Why?
|
| Anemia | 2 | 1996 | 350 | 0.170 |
Why?
|
| Positron Emission Tomography Computed Tomography | 2 | 2019 | 79 | 0.170 |
Why?
|
| Gene Expression Regulation | 2 | 2009 | 2442 | 0.170 |
Why?
|
| Pleurodesis | 1 | 2020 | 15 | 0.170 |
Why?
|
| Herpesvirus 6, Human | 3 | 2003 | 55 | 0.170 |
Why?
|
| Liver Diseases | 2 | 2018 | 385 | 0.170 |
Why?
|
| Chest Tubes | 1 | 2020 | 37 | 0.170 |
Why?
|
| Molecular Biology | 1 | 2020 | 73 | 0.160 |
Why?
|
| Cladribine | 3 | 2022 | 9 | 0.160 |
Why?
|
| Child Abuse | 1 | 2003 | 204 | 0.160 |
Why?
|
| Leiomyoma | 4 | 1997 | 83 | 0.160 |
Why?
|
| Treatment Outcome | 13 | 2024 | 13027 | 0.160 |
Why?
|
| Chemoradiotherapy | 2 | 2018 | 125 | 0.160 |
Why?
|
| Fatal Outcome | 4 | 2010 | 376 | 0.160 |
Why?
|
| Leukemia, B-Cell | 1 | 2000 | 25 | 0.160 |
Why?
|
| Skin | 3 | 2021 | 527 | 0.160 |
Why?
|
| Young Adult | 7 | 2025 | 9966 | 0.160 |
Why?
|
| Diabetes Insipidus | 4 | 2010 | 16 | 0.160 |
Why?
|
| Cellular Senescence | 1 | 2021 | 201 | 0.160 |
Why?
|
| HIV Infections | 6 | 2003 | 2050 | 0.150 |
Why?
|
| Tertiary Healthcare | 1 | 2019 | 20 | 0.150 |
Why?
|
| Macrophage Activation | 1 | 2019 | 65 | 0.150 |
Why?
|
| Cytokines | 4 | 2021 | 1365 | 0.150 |
Why?
|
| Cytomegalovirus Infections | 5 | 2003 | 224 | 0.150 |
Why?
|
| Drug Eruptions | 1 | 2019 | 34 | 0.150 |
Why?
|
| Translocation, Genetic | 3 | 2014 | 358 | 0.150 |
Why?
|
| Practice Guidelines as Topic | 5 | 2018 | 1307 | 0.150 |
Why?
|
| Tomography, X-Ray Computed | 5 | 2013 | 2166 | 0.150 |
Why?
|
| Age of Onset | 2 | 2019 | 626 | 0.150 |
Why?
|
| Consensus | 3 | 2022 | 658 | 0.150 |
Why?
|
| Virus Diseases | 2 | 1994 | 289 | 0.150 |
Why?
|
| Lymphoma, T-Cell | 1 | 2019 | 63 | 0.150 |
Why?
|
| Liver Failure | 1 | 2019 | 91 | 0.150 |
Why?
|
| Biliary Tract Diseases | 1 | 2018 | 37 | 0.150 |
Why?
|
| Disseminated Intravascular Coagulation | 1 | 2018 | 66 | 0.140 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2018 | 93 | 0.140 |
Why?
|
| Brain | 3 | 2023 | 3194 | 0.140 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2021 | 449 | 0.140 |
Why?
|
| Survival Rate | 5 | 2017 | 2196 | 0.140 |
Why?
|
| Metabolism, Inborn Errors | 1 | 2019 | 120 | 0.140 |
Why?
|
| Dexamethasone | 2 | 2017 | 273 | 0.140 |
Why?
|
| Infant, Premature, Diseases | 2 | 1997 | 252 | 0.140 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2021 | 503 | 0.140 |
Why?
|
| Epstein-Barr Virus Nuclear Antigens | 2 | 1999 | 60 | 0.140 |
Why?
|
| Smad6 Protein | 1 | 2017 | 8 | 0.140 |
Why?
|
| B-Lymphocytes | 5 | 1997 | 543 | 0.140 |
Why?
|
| Immunoglobulins, Intravenous | 3 | 2015 | 150 | 0.140 |
Why?
|
| Philadelphia Chromosome | 2 | 2014 | 43 | 0.140 |
Why?
|
| Fusion Proteins, bcr-abl | 2 | 2014 | 43 | 0.140 |
Why?
|
| Adenovirus Infections, Human | 2 | 1994 | 57 | 0.130 |
Why?
|
| Etoposide | 1 | 2017 | 121 | 0.130 |
Why?
|
| Parvovirus | 2 | 1994 | 8 | 0.130 |
Why?
|
| Lymphotoxin-alpha | 1 | 1997 | 8 | 0.130 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 6 | 2008 | 815 | 0.130 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2017 | 109 | 0.130 |
Why?
|
| Antimetabolites, Antineoplastic | 2 | 2013 | 194 | 0.130 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2018 | 3358 | 0.130 |
Why?
|
| Bone Marrow Cells | 2 | 2017 | 258 | 0.120 |
Why?
|
| Thiophenes | 1 | 2016 | 69 | 0.120 |
Why?
|
| Neoadjuvant Therapy | 1 | 2018 | 400 | 0.120 |
Why?
|
| Alemtuzumab | 4 | 2023 | 88 | 0.120 |
Why?
|
| Neutropenia | 2 | 1994 | 205 | 0.120 |
Why?
|
| Fetal Diseases | 1 | 2019 | 461 | 0.120 |
Why?
|
| Radiation Dosage | 2 | 2013 | 146 | 0.120 |
Why?
|
| Genetic Testing | 2 | 2021 | 1099 | 0.110 |
Why?
|
| Doxorubicin | 5 | 2008 | 303 | 0.110 |
Why?
|
| Vaginal Diseases | 1 | 2015 | 16 | 0.110 |
Why?
|
| Organophosphate Poisoning | 1 | 1994 | 4 | 0.110 |
Why?
|
| Thoracic Surgery, Video-Assisted | 1 | 2015 | 56 | 0.110 |
Why?
|
| Prothrombin Time | 1 | 1994 | 38 | 0.110 |
Why?
|
| Perforin | 1 | 2014 | 26 | 0.110 |
Why?
|
| Risk Factors | 9 | 2018 | 10945 | 0.110 |
Why?
|
| Poisoning | 1 | 1994 | 18 | 0.110 |
Why?
|
| Arthritis, Juvenile | 1 | 2015 | 42 | 0.110 |
Why?
|
| Antigens | 1 | 2015 | 149 | 0.110 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2016 | 234 | 0.110 |
Why?
|
| MAP Kinase Kinase 1 | 1 | 2014 | 44 | 0.110 |
Why?
|
| Vitamin K | 1 | 1994 | 38 | 0.110 |
Why?
|
| Glycoproteins | 3 | 2020 | 377 | 0.110 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2010 | 1045 | 0.110 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 1 | 2014 | 56 | 0.110 |
Why?
|
| Immune System | 1 | 2015 | 97 | 0.110 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 1995 | 138 | 0.110 |
Why?
|
| Cell Movement | 1 | 2017 | 890 | 0.110 |
Why?
|
| Pyrazoles | 1 | 2016 | 329 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2016 | 502 | 0.100 |
Why?
|
| Registries | 3 | 2018 | 1591 | 0.100 |
Why?
|
| HIV | 4 | 2002 | 190 | 0.100 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 3 | 2000 | 64 | 0.100 |
Why?
|
| Genome-Wide Association Study | 2 | 2018 | 1831 | 0.100 |
Why?
|
| Phagocytosis | 3 | 2017 | 191 | 0.100 |
Why?
|
| Early Detection of Cancer | 1 | 2017 | 414 | 0.100 |
Why?
|
| Aged | 9 | 2024 | 21482 | 0.100 |
Why?
|
| Texas | 5 | 2018 | 3632 | 0.100 |
Why?
|
| Soft Tissue Neoplasms | 1 | 1995 | 127 | 0.100 |
Why?
|
| Erythrocytes | 1 | 1993 | 201 | 0.100 |
Why?
|
| Case-Control Studies | 6 | 2018 | 3414 | 0.100 |
Why?
|
| Pregnancy Complications, Infectious | 2 | 1997 | 496 | 0.100 |
Why?
|
| Antibodies, Monoclonal | 3 | 2011 | 1036 | 0.100 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2018 | 946 | 0.100 |
Why?
|
| Antigens, CD1 | 3 | 2020 | 23 | 0.100 |
Why?
|
| STAT3 Transcription Factor | 1 | 2014 | 232 | 0.100 |
Why?
|
| T-Lymphocytes | 3 | 2019 | 1757 | 0.090 |
Why?
|
| Mice | 6 | 2021 | 18507 | 0.090 |
Why?
|
| DNA | 1 | 1997 | 1479 | 0.090 |
Why?
|
| Base Sequence | 6 | 1995 | 2900 | 0.090 |
Why?
|
| Neoplasm Staging | 4 | 2013 | 1365 | 0.090 |
Why?
|
| Treatment Failure | 2 | 2025 | 364 | 0.090 |
Why?
|
| Genome, Human | 1 | 2018 | 1331 | 0.090 |
Why?
|
| Lymphocyte Activation | 4 | 2007 | 686 | 0.090 |
Why?
|
| Molecular Sequence Data | 6 | 1995 | 3771 | 0.090 |
Why?
|
| ROC Curve | 2 | 2014 | 600 | 0.090 |
Why?
|
| Parents | 1 | 2018 | 1080 | 0.090 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2011 | 826 | 0.090 |
Why?
|
| Genetic Diseases, Inborn | 1 | 2014 | 459 | 0.080 |
Why?
|
| Muscle, Smooth | 3 | 1999 | 131 | 0.080 |
Why?
|
| Cytomegalovirus | 3 | 2002 | 262 | 0.080 |
Why?
|
| Histiocytic Sarcoma | 1 | 2010 | 4 | 0.080 |
Why?
|
| Reproducibility of Results | 1 | 2017 | 3018 | 0.080 |
Why?
|
| Radiography | 3 | 2009 | 818 | 0.080 |
Why?
|
| Critical Illness | 1 | 2015 | 618 | 0.080 |
Why?
|
| Lymphoma | 3 | 1997 | 331 | 0.080 |
Why?
|
| Nucleic Acid Hybridization | 4 | 1997 | 311 | 0.080 |
Why?
|
| CD3 Complex | 1 | 2010 | 92 | 0.080 |
Why?
|
| Animals | 8 | 2021 | 34850 | 0.080 |
Why?
|
| Lymphatic Diseases | 2 | 1988 | 31 | 0.080 |
Why?
|
| Herpesvirus 8, Human | 2 | 2000 | 49 | 0.080 |
Why?
|
| Systemic Inflammatory Response Syndrome | 2 | 2021 | 198 | 0.080 |
Why?
|
| Mortality | 1 | 2011 | 263 | 0.080 |
Why?
|
| Blood Cells | 1 | 2019 | 55 | 0.080 |
Why?
|
| Clone Cells | 5 | 1998 | 179 | 0.080 |
Why?
|
| Postoperative Complications | 3 | 1990 | 3139 | 0.070 |
Why?
|
| Genotype | 1 | 2015 | 2703 | 0.070 |
Why?
|
| Thalassemia | 1 | 2008 | 11 | 0.070 |
Why?
|
| Virus Activation | 2 | 2008 | 86 | 0.070 |
Why?
|
| Gene Amplification | 1 | 2009 | 240 | 0.070 |
Why?
|
| Iron Overload | 1 | 2008 | 16 | 0.070 |
Why?
|
| Biomarkers, Tumor | 2 | 2014 | 1683 | 0.070 |
Why?
|
| DNA Primers | 3 | 2007 | 636 | 0.070 |
Why?
|
| Meningeal Neoplasms | 1 | 1990 | 216 | 0.070 |
Why?
|
| Liver | 2 | 2019 | 1797 | 0.070 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2008 | 63 | 0.070 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2013 | 1304 | 0.070 |
Why?
|
| Asparaginase | 1 | 2008 | 49 | 0.070 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2009 | 123 | 0.070 |
Why?
|
| CD8 Antigens | 1 | 2007 | 45 | 0.070 |
Why?
|
| Eosinophilic Granuloma | 1 | 1987 | 3 | 0.070 |
Why?
|
| Cell Division | 1 | 2009 | 744 | 0.070 |
Why?
|
| Odds Ratio | 1 | 2011 | 1255 | 0.070 |
Why?
|
| Fever | 3 | 2009 | 310 | 0.070 |
Why?
|
| RNA, Messenger | 2 | 2011 | 2680 | 0.070 |
Why?
|
| Methylprednisolone | 1 | 1987 | 98 | 0.070 |
Why?
|
| Erythrocyte Transfusion | 1 | 2008 | 138 | 0.060 |
Why?
|
| Mycoses | 1 | 2008 | 117 | 0.060 |
Why?
|
| Kidney Transplantation | 2 | 1990 | 571 | 0.060 |
Why?
|
| Cell Survival | 1 | 2009 | 868 | 0.060 |
Why?
|
| Orbital Diseases | 1 | 1987 | 72 | 0.060 |
Why?
|
| Mice, Inbred C57BL | 3 | 2021 | 4758 | 0.060 |
Why?
|
| Databases, Genetic | 1 | 2019 | 502 | 0.060 |
Why?
|
| Bacterial Infections | 1 | 2009 | 323 | 0.060 |
Why?
|
| Remission, Spontaneous | 2 | 2002 | 69 | 0.060 |
Why?
|
| DNA Mutational Analysis | 2 | 2009 | 826 | 0.060 |
Why?
|
| Cell Proliferation | 2 | 2021 | 2511 | 0.060 |
Why?
|
| Skull | 1 | 1987 | 143 | 0.060 |
Why?
|
| Down Syndrome | 1 | 1989 | 232 | 0.060 |
Why?
|
| In Situ Hybridization | 3 | 1997 | 469 | 0.060 |
Why?
|
| Prospective Studies | 5 | 2020 | 6568 | 0.060 |
Why?
|
| Genes, Immunoglobulin | 2 | 2000 | 33 | 0.060 |
Why?
|
| Disease Progression | 3 | 2018 | 2233 | 0.060 |
Why?
|
| Pituitary Diseases | 1 | 2025 | 11 | 0.060 |
Why?
|
| Immunoglobulins | 5 | 1990 | 169 | 0.060 |
Why?
|
| Roseolovirus Infections | 2 | 2003 | 30 | 0.060 |
Why?
|
| Hematopoietic Cell Growth Factors | 1 | 2005 | 11 | 0.060 |
Why?
|
| Retroviridae | 4 | 1998 | 194 | 0.060 |
Why?
|
| Pedigree | 3 | 2009 | 1724 | 0.060 |
Why?
|
| Antibodies, Neoplasm | 1 | 2005 | 59 | 0.060 |
Why?
|
| Herpes Zoster | 1 | 1985 | 26 | 0.060 |
Why?
|
| Nucleic Acid Amplification Techniques | 1 | 2005 | 71 | 0.060 |
Why?
|
| Neoplasms, Second Primary | 2 | 2004 | 149 | 0.050 |
Why?
|
| Tissue Donors | 2 | 2023 | 503 | 0.050 |
Why?
|
| Anemia, Sickle Cell | 1 | 2008 | 330 | 0.050 |
Why?
|
| Secondary Prevention | 1 | 2005 | 219 | 0.050 |
Why?
|
| Oncogenes | 1 | 1984 | 177 | 0.050 |
Why?
|
| Models, Biological | 1 | 2009 | 1445 | 0.050 |
Why?
|
| Lymphocyte Subsets | 1 | 2003 | 41 | 0.050 |
Why?
|
| Chemokine CXCL9 | 1 | 2023 | 14 | 0.050 |
Why?
|
| Melphalan | 1 | 2023 | 46 | 0.050 |
Why?
|
| Leukemia | 2 | 1997 | 372 | 0.050 |
Why?
|
| Multiple Organ Failure | 2 | 2018 | 145 | 0.050 |
Why?
|
| Combined Modality Therapy | 4 | 2010 | 1294 | 0.050 |
Why?
|
| Sensitivity and Specificity | 1 | 2008 | 2139 | 0.050 |
Why?
|
| Cell Lineage | 2 | 2015 | 358 | 0.050 |
Why?
|
| DNA Probes | 3 | 1994 | 124 | 0.050 |
Why?
|
| Neoplastic Stem Cells | 2 | 1997 | 348 | 0.050 |
Why?
|
| Apoptosis | 2 | 2021 | 1901 | 0.050 |
Why?
|
| MutS Homolog 2 Protein | 1 | 2022 | 39 | 0.050 |
Why?
|
| MutL Protein Homolog 1 | 1 | 2022 | 52 | 0.050 |
Why?
|
| Mucocutaneous Lymph Node Syndrome | 1 | 2003 | 73 | 0.050 |
Why?
|
| DNA Mismatch Repair | 1 | 2022 | 54 | 0.050 |
Why?
|
| Antigens, Neoplasm | 1 | 2005 | 403 | 0.050 |
Why?
|
| Fatigue | 1 | 2023 | 201 | 0.050 |
Why?
|
| Genetic Markers | 2 | 2007 | 618 | 0.050 |
Why?
|
| Head | 1 | 2022 | 115 | 0.050 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 2022 | 74 | 0.050 |
Why?
|
| Hyperplasia | 2 | 1993 | 196 | 0.050 |
Why?
|
| Multicenter Studies as Topic | 1 | 2002 | 312 | 0.040 |
Why?
|
| CD11c Antigen | 2 | 2014 | 40 | 0.040 |
Why?
|
| T-Lymphocytes, Cytotoxic | 2 | 1998 | 520 | 0.040 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2023 | 213 | 0.040 |
Why?
|
| Meningitis, Aseptic | 1 | 2001 | 14 | 0.040 |
Why?
|
| Immunohistochemistry | 3 | 2017 | 1718 | 0.040 |
Why?
|
| Antibodies, Viral | 6 | 1996 | 1204 | 0.040 |
Why?
|
| Drug Synergism | 1 | 2021 | 235 | 0.040 |
Why?
|
| Immunity | 1 | 2021 | 183 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2005 | 1249 | 0.040 |
Why?
|
| Mice, Transgenic | 2 | 2021 | 2451 | 0.040 |
Why?
|
| Autoimmunity | 1 | 2021 | 181 | 0.040 |
Why?
|
| Viral Matrix Proteins | 2 | 1999 | 110 | 0.040 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 1 | 2000 | 70 | 0.040 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2021 | 200 | 0.040 |
Why?
|
| Pain | 1 | 2023 | 462 | 0.040 |
Why?
|
| Thrombocytopenia | 2 | 1997 | 233 | 0.040 |
Why?
|
| Follow-Up Studies | 3 | 2019 | 5410 | 0.040 |
Why?
|
| Neoplasms, Multiple Primary | 2 | 2010 | 64 | 0.040 |
Why?
|
| Genes, myc | 1 | 2000 | 103 | 0.040 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2000 | 275 | 0.040 |
Why?
|
| Transcription, Genetic | 1 | 1984 | 1423 | 0.040 |
Why?
|
| Cells, Cultured | 2 | 2017 | 3046 | 0.040 |
Why?
|
| Immunophenotyping | 2 | 2017 | 343 | 0.040 |
Why?
|
| Proteome | 1 | 2021 | 279 | 0.040 |
Why?
|
| Neuroimaging | 1 | 2022 | 375 | 0.040 |
Why?
|
| Flucytosine | 1 | 1979 | 17 | 0.040 |
Why?
|
| Sirolimus | 1 | 2021 | 241 | 0.040 |
Why?
|
| Oximes | 1 | 2019 | 56 | 0.040 |
Why?
|
| Interferon-gamma | 1 | 2021 | 539 | 0.040 |
Why?
|
| Cytosine | 1 | 1979 | 58 | 0.040 |
Why?
|
| Cryptococcosis | 1 | 1979 | 45 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 2 | 1999 | 1045 | 0.040 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2021 | 446 | 0.040 |
Why?
|
| Procarbazine | 3 | 1999 | 12 | 0.040 |
Why?
|
| Neomycin | 1 | 1998 | 36 | 0.040 |
Why?
|
| Spinal Neoplasms | 1 | 1999 | 74 | 0.040 |
Why?
|
| Lung | 3 | 2002 | 1556 | 0.040 |
Why?
|
| Imidazoles | 1 | 2019 | 219 | 0.030 |
Why?
|
| Mutation, Missense | 2 | 2014 | 937 | 0.030 |
Why?
|
| Genome, Viral | 2 | 1997 | 179 | 0.030 |
Why?
|
| Genetic Association Studies | 1 | 2021 | 857 | 0.030 |
Why?
|
| Molecular Targeted Therapy | 1 | 2020 | 403 | 0.030 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2018 | 337 | 0.030 |
Why?
|
| Leukemia, Myeloid, Acute | 3 | 1989 | 570 | 0.030 |
Why?
|
| Killer Cells, Natural | 3 | 2009 | 351 | 0.030 |
Why?
|
| Lipopolysaccharide Receptors | 1 | 2017 | 53 | 0.030 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2020 | 635 | 0.030 |
Why?
|
| Radiotherapy | 1 | 2018 | 145 | 0.030 |
Why?
|
| Foam Cells | 1 | 2017 | 24 | 0.030 |
Why?
|
| Hydrops Fetalis | 1 | 1997 | 85 | 0.030 |
Why?
|
| Diseases in Twins | 1 | 1997 | 97 | 0.030 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2017 | 68 | 0.030 |
Why?
|
| Drug Therapy | 1 | 2017 | 87 | 0.030 |
Why?
|
| Multifactorial Inheritance | 1 | 2018 | 167 | 0.030 |
Why?
|
| Viruses | 1 | 1998 | 126 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2011 | 1285 | 0.030 |
Why?
|
| Leukemia, Lymphoid | 2 | 1988 | 103 | 0.030 |
Why?
|
| United States | 4 | 2016 | 11669 | 0.030 |
Why?
|
| DNA-Binding Proteins | 2 | 2022 | 1997 | 0.030 |
Why?
|
| Cohort Studies | 2 | 2018 | 5176 | 0.030 |
Why?
|
| Mexico | 1 | 2016 | 186 | 0.030 |
Why?
|
| Survival Analysis | 2 | 2014 | 1574 | 0.030 |
Why?
|
| Cause of Death | 1 | 2018 | 509 | 0.030 |
Why?
|
| DNA, Complementary | 1 | 1997 | 454 | 0.030 |
Why?
|
| Colorectal Neoplasms | 1 | 2022 | 630 | 0.030 |
Why?
|
| Probability | 2 | 2008 | 322 | 0.030 |
Why?
|
| Pregnancy | 3 | 2018 | 7557 | 0.030 |
Why?
|
| Protein Domains | 1 | 2016 | 260 | 0.030 |
Why?
|
| Stem Cell Transplantation | 1 | 2017 | 249 | 0.030 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 1997 | 253 | 0.030 |
Why?
|
| Enzyme Activation | 1 | 2016 | 618 | 0.030 |
Why?
|
| Receptors, Notch | 1 | 2017 | 212 | 0.030 |
Why?
|
| Monocytes | 1 | 2017 | 342 | 0.030 |
Why?
|
| Sarcoma, Kaposi | 1 | 1996 | 131 | 0.030 |
Why?
|
| Alleles | 2 | 2017 | 1685 | 0.030 |
Why?
|
| Respiratory Insufficiency | 1 | 1997 | 247 | 0.030 |
Why?
|
| Fever of Unknown Origin | 1 | 2015 | 45 | 0.030 |
Why?
|
| Drug Substitution | 1 | 2014 | 20 | 0.030 |
Why?
|
| Factor VII | 1 | 1994 | 18 | 0.030 |
Why?
|
| Deltaretrovirus | 1 | 1994 | 5 | 0.030 |
Why?
|
| Infant, Premature | 2 | 1997 | 843 | 0.030 |
Why?
|
| Acetylcholinesterase | 1 | 1994 | 23 | 0.030 |
Why?
|
| Blotting, Southern | 1 | 1994 | 213 | 0.030 |
Why?
|
| Aerosols | 1 | 1994 | 64 | 0.030 |
Why?
|
| Sequence Deletion | 1 | 1997 | 526 | 0.030 |
Why?
|
| Masks | 1 | 1994 | 40 | 0.030 |
Why?
|
| Transforming Growth Factor beta | 1 | 2017 | 473 | 0.030 |
Why?
|
| Flow Cytometry | 2 | 2014 | 802 | 0.030 |
Why?
|
| STAT1 Transcription Factor | 1 | 2014 | 76 | 0.030 |
Why?
|
| Simplexvirus | 1 | 1994 | 100 | 0.030 |
Why?
|
| Respiration | 1 | 1994 | 123 | 0.030 |
Why?
|
| Adenoviruses, Human | 1 | 1994 | 97 | 0.030 |
Why?
|
| STAT5 Transcription Factor | 1 | 2014 | 91 | 0.030 |
Why?
|
| Family | 1 | 2017 | 595 | 0.030 |
Why?
|
| Mechlorethamine | 2 | 1993 | 7 | 0.030 |
Why?
|
| Saliva | 1 | 1994 | 133 | 0.030 |
Why?
|
| Antigens, CD34 | 1 | 2014 | 109 | 0.030 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 1994 | 95 | 0.030 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2014 | 84 | 0.030 |
Why?
|
| Antigens, Surface | 1 | 2014 | 117 | 0.030 |
Why?
|
| Cyclophosphamide | 2 | 1999 | 426 | 0.030 |
Why?
|
| Central Nervous System Neoplasms | 1 | 1996 | 215 | 0.030 |
Why?
|
| Hemangioma, Cavernous | 1 | 1993 | 20 | 0.030 |
Why?
|
| Bleomycin | 2 | 1993 | 113 | 0.030 |
Why?
|
| Dacarbazine | 2 | 1993 | 98 | 0.030 |
Why?
|
| Tranexamic Acid | 1 | 1993 | 33 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2017 | 1500 | 0.030 |
Why?
|
| Placenta | 1 | 1997 | 539 | 0.020 |
Why?
|
| Radiopharmaceuticals | 1 | 2013 | 170 | 0.020 |
Why?
|
| Pons | 1 | 1993 | 35 | 0.020 |
Why?
|
| Demyelinating Diseases | 1 | 1993 | 70 | 0.020 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2014 | 234 | 0.020 |
Why?
|
| Gene Expression | 1 | 2017 | 1563 | 0.020 |
Why?
|
| Hemangioma | 1 | 1993 | 97 | 0.020 |
Why?
|
| Escherichia coli Infections | 1 | 1994 | 192 | 0.020 |
Why?
|
| Risk Assessment | 2 | 2017 | 3736 | 0.020 |
Why?
|
| Hemoglobins | 1 | 1993 | 322 | 0.020 |
Why?
|
| Cross-Sectional Studies | 2 | 2013 | 3761 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2014 | 799 | 0.020 |
Why?
|
| Blotting, Western | 2 | 2011 | 1080 | 0.020 |
Why?
|
| Adenoviridae | 1 | 1994 | 596 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2014 | 881 | 0.020 |
Why?
|
| Alanine Transaminase | 1 | 2012 | 162 | 0.020 |
Why?
|
| Spleen | 2 | 2010 | 271 | 0.020 |
Why?
|
| Neutrophils | 1 | 1993 | 360 | 0.020 |
Why?
|
| Prevalence | 3 | 2004 | 2664 | 0.020 |
Why?
|
| Immunoprecipitation | 1 | 2011 | 196 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2014 | 1461 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2014 | 1612 | 0.020 |
Why?
|
| Intestine, Large | 1 | 1990 | 14 | 0.020 |
Why?
|
| Agammaglobulinemia | 1 | 1990 | 44 | 0.020 |
Why?
|
| Autoantibodies | 1 | 1993 | 458 | 0.020 |
Why?
|
| Lomustine | 1 | 1990 | 2 | 0.020 |
Why?
|
| Radiotherapy, High-Energy | 1 | 1990 | 5 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2021 | 4690 | 0.020 |
Why?
|
| Pilot Projects | 2 | 2005 | 1444 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2013 | 1128 | 0.020 |
Why?
|
| Intestinal Neoplasms | 1 | 1990 | 40 | 0.020 |
Why?
|
| Signaling Lymphocytic Activation Molecule Associated Protein | 1 | 2009 | 3 | 0.020 |
Why?
|
| Minnesota | 1 | 1990 | 180 | 0.020 |
Why?
|
| Age Distribution | 2 | 2003 | 437 | 0.020 |
Why?
|
| Infectious Mononucleosis | 2 | 1992 | 15 | 0.020 |
Why?
|
| Family Health | 1 | 2010 | 256 | 0.020 |
Why?
|
| Chlorambucil | 1 | 1989 | 5 | 0.020 |
Why?
|
| Chromosome Banding | 2 | 1989 | 140 | 0.020 |
Why?
|
| Chronic Disease | 1 | 1993 | 1233 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 7 | 1 | 1989 | 76 | 0.020 |
Why?
|
| Diabetes Insipidus, Neurogenic | 1 | 2008 | 5 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 1989 | 94 | 0.020 |
Why?
|
| Leukemia Virus, Bovine | 1 | 1988 | 2 | 0.020 |
Why?
|
| Infusions, Intravenous | 2 | 2004 | 547 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2017 | 2851 | 0.020 |
Why?
|
| Lung Neoplasms | 2 | 1990 | 1541 | 0.020 |
Why?
|
| Anemia, Aplastic | 1 | 1988 | 60 | 0.020 |
Why?
|
| Receptors, Antigen, T-Cell | 2 | 1989 | 499 | 0.020 |
Why?
|
| Karyotyping | 2 | 1985 | 317 | 0.020 |
Why?
|
| United Kingdom | 1 | 2008 | 234 | 0.020 |
Why?
|
| Age Factors | 1 | 2014 | 2923 | 0.020 |
Why?
|
| Myelodysplastic Syndromes | 1 | 1989 | 128 | 0.020 |
Why?
|
| International Cooperation | 1 | 2008 | 167 | 0.020 |
Why?
|
| Genes | 1 | 1988 | 313 | 0.020 |
Why?
|
| Mice, Inbred Strains | 1 | 2007 | 308 | 0.020 |
Why?
|
| Canada | 1 | 2008 | 337 | 0.020 |
Why?
|
| Injections | 1 | 1987 | 152 | 0.020 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2009 | 579 | 0.020 |
Why?
|
| Green Fluorescent Proteins | 1 | 2007 | 395 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 1998 | 2552 | 0.020 |
Why?
|
| Cerebellum | 1 | 2010 | 464 | 0.020 |
Why?
|
| Risk | 1 | 2008 | 761 | 0.020 |
Why?
|
| Syndrome | 2 | 1986 | 1175 | 0.020 |
Why?
|
| Chediak-Higashi Syndrome | 1 | 1985 | 1 | 0.020 |
Why?
|
| Serotyping | 1 | 1986 | 178 | 0.010 |
Why?
|
| Chromosome Deletion | 1 | 1989 | 656 | 0.010 |
Why?
|
| Leukemia, Monocytic, Acute | 1 | 1985 | 4 | 0.010 |
Why?
|
| Mediastinal Neoplasms | 1 | 1985 | 42 | 0.010 |
Why?
|
| Tumor Stem Cell Assay | 2 | 1997 | 37 | 0.010 |
Why?
|
| Whole-Body Irradiation | 1 | 1985 | 60 | 0.010 |
Why?
|
| CD52 Antigen | 1 | 2005 | 7 | 0.010 |
Why?
|
| Stem Cell Factor | 1 | 2005 | 12 | 0.010 |
Why?
|
| Macrophage Colony-Stimulating Factor | 1 | 2005 | 17 | 0.010 |
Why?
|
| Chromosomes, Human, 6-12 and X | 1 | 1985 | 2 | 0.010 |
Why?
|
| Chromosomes, Human, 13-15 | 1 | 1985 | 4 | 0.010 |
Why?
|
| Myeloid Progenitor Cells | 1 | 2005 | 15 | 0.010 |
Why?
|
| Homosexuality | 1 | 1985 | 14 | 0.010 |
Why?
|
| Clinical Enzyme Tests | 1 | 1985 | 16 | 0.010 |
Why?
|
| Vasculitis | 1 | 1985 | 50 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2017 | 4720 | 0.010 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 1985 | 67 | 0.010 |
Why?
|
| Testicular Neoplasms | 1 | 1985 | 132 | 0.010 |
Why?
|
| Sarcoma, Ewing | 1 | 1985 | 116 | 0.010 |
Why?
|
| Teratoma | 1 | 1985 | 129 | 0.010 |
Why?
|
| DNA, Neoplasm | 2 | 1997 | 295 | 0.010 |
Why?
|
| Leukocyte Count | 1 | 2005 | 249 | 0.010 |
Why?
|
| Leukemia, Myeloid | 1 | 1984 | 81 | 0.010 |
Why?
|
| Wilms Tumor | 1 | 1985 | 119 | 0.010 |
Why?
|
| Chickens | 1 | 1984 | 302 | 0.010 |
Why?
|
| Isoenzymes | 1 | 1985 | 222 | 0.010 |
Why?
|
| Ligands | 1 | 2005 | 495 | 0.010 |
Why?
|
| Consanguinity | 1 | 2003 | 121 | 0.010 |
Why?
|
| Australia | 1 | 2003 | 185 | 0.010 |
Why?
|
| Anemia, Hypochromic | 1 | 1983 | 7 | 0.010 |
Why?
|
| Vulva | 1 | 2003 | 16 | 0.010 |
Why?
|
| Osteosarcoma | 1 | 1985 | 263 | 0.010 |
Why?
|
| Erythema | 1 | 1983 | 29 | 0.010 |
Why?
|
| Neurilemmoma | 1 | 2003 | 48 | 0.010 |
Why?
|
| DNA Replication | 1 | 1985 | 353 | 0.010 |
Why?
|
| Splenomegaly | 1 | 1983 | 32 | 0.010 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2003 | 235 | 0.010 |
Why?
|
| Europe | 1 | 2003 | 373 | 0.010 |
Why?
|
| Chromosome Disorders | 1 | 1985 | 311 | 0.010 |
Why?
|
| Rhabdomyosarcoma | 1 | 1985 | 215 | 0.010 |
Why?
|
| Scalp | 1 | 2003 | 57 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 2003 | 588 | 0.010 |
Why?
|
| Data Collection | 1 | 2004 | 391 | 0.010 |
Why?
|
| Chromosome Aberrations | 1 | 1985 | 590 | 0.010 |
Why?
|
| Hearing Loss | 1 | 2004 | 212 | 0.010 |
Why?
|
| Aspirin | 1 | 2003 | 220 | 0.010 |
Why?
|
| Regression Analysis | 1 | 2003 | 796 | 0.010 |
Why?
|
| Lymphatic Metastasis | 1 | 2002 | 444 | 0.010 |
Why?
|
| Kidney Neoplasms | 1 | 1985 | 451 | 0.010 |
Why?
|
| Viral Load | 1 | 2003 | 408 | 0.010 |
Why?
|
| Hepatoblastoma | 1 | 2003 | 183 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2004 | 1671 | 0.010 |
Why?
|
| Recombinant Proteins | 2 | 1994 | 1350 | 0.010 |
Why?
|
| Neuroblastoma | 1 | 1985 | 550 | 0.010 |
Why?
|
| Societies, Medical | 1 | 2004 | 778 | 0.010 |
Why?
|
| X Chromosome | 2 | 1994 | 340 | 0.010 |
Why?
|
| Anti-HIV Agents | 1 | 2002 | 348 | 0.010 |
Why?
|
| Receptors, Complement 3d | 1 | 1999 | 8 | 0.010 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 1999 | 68 | 0.010 |
Why?
|
| Gene Products, env | 1 | 1999 | 17 | 0.010 |
Why?
|
| Microscopy, Phase-Contrast | 1 | 1999 | 15 | 0.010 |
Why?
|
| env Gene Products, Human Immunodeficiency Virus | 1 | 1999 | 12 | 0.010 |
Why?
|
| Incidence | 2 | 1997 | 3376 | 0.010 |
Why?
|
| Prednisolone | 1 | 1999 | 73 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 1999 | 81 | 0.010 |
Why?
|
| Cell Transformation, Viral | 1 | 1999 | 98 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 1999 | 98 | 0.010 |
Why?
|
| Virus Latency | 1 | 1999 | 64 | 0.010 |
Why?
|
| Rats | 1 | 1984 | 3607 | 0.010 |
Why?
|
| Protein Precursors | 1 | 1999 | 156 | 0.010 |
Why?
|
| Injections, Intravenous | 1 | 1998 | 247 | 0.010 |
Why?
|
| HIV Core Protein p24 | 1 | 1997 | 12 | 0.010 |
Why?
|
| Drug Resistance, Microbial | 1 | 1998 | 197 | 0.010 |
Why?
|
| Czech Republic | 1 | 1997 | 12 | 0.010 |
Why?
|
| Sialadenitis | 1 | 1997 | 2 | 0.010 |
Why?
|
| Antiviral Agents | 1 | 2003 | 823 | 0.010 |
Why?
|
| Calcium-Binding Proteins | 1 | 1999 | 333 | 0.010 |
Why?
|
| Salivary Glands | 1 | 1997 | 34 | 0.010 |
Why?
|
| Palatine Tonsil | 1 | 1997 | 36 | 0.010 |
Why?
|
| Serologic Tests | 1 | 1997 | 130 | 0.010 |
Why?
|
| Lymphoid Tissue | 1 | 1997 | 50 | 0.010 |
Why?
|
| Membrane Proteins | 1 | 2005 | 1597 | 0.010 |
Why?
|
| Hematology | 1 | 1997 | 41 | 0.010 |
Why?
|
| Antigens, Viral | 1 | 1999 | 439 | 0.010 |
Why?
|
| Viral Proteins | 1 | 1999 | 357 | 0.010 |
Why?
|
| Microfilament Proteins | 1 | 1999 | 285 | 0.010 |
Why?
|
| Administration, Oral | 1 | 1979 | 699 | 0.010 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 1997 | 167 | 0.010 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 1985 | 984 | 0.010 |
Why?
|
| Actins | 1 | 1999 | 334 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 1997 | 811 | 0.010 |
Why?
|
| Neoplasm, Residual | 1 | 1997 | 134 | 0.010 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 1997 | 396 | 0.010 |
Why?
|
| Medical Oncology | 1 | 1997 | 244 | 0.010 |
Why?
|
| Sex Distribution | 1 | 1996 | 327 | 0.010 |
Why?
|
| Virus Replication | 1 | 1999 | 636 | 0.010 |
Why?
|
| SEER Program | 1 | 1996 | 220 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 1998 | 821 | 0.010 |
Why?
|
| Liver Neoplasms | 1 | 1985 | 1381 | 0.010 |
Why?
|
| Trans-Activators | 1 | 1999 | 712 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2003 | 3093 | 0.010 |
Why?
|
| Genetic Vectors | 1 | 1998 | 927 | 0.010 |
Why?
|
| Cell Line | 1 | 1998 | 2724 | 0.010 |
Why?
|
| Lymphomatoid Granulomatosis | 1 | 1992 | 3 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2003 | 7138 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 1993 | 749 | 0.010 |
Why?
|
| Pulmonary Fibrosis | 1 | 1992 | 112 | 0.010 |
Why?
|
| HLA Antigens | 1 | 1992 | 219 | 0.010 |
Why?
|
| Sarcoma Virus, Woolly Monkey | 1 | 1989 | 1 | 0.000 |
Why?
|
| DNA Nucleotidylexotransferase | 1 | 1989 | 8 | 0.000 |
Why?
|
| Antigenic Variation | 1 | 1989 | 42 | 0.000 |
Why?
|
| Staining and Labeling | 1 | 1989 | 181 | 0.000 |
Why?
|
| Lymphocyte Depletion | 1 | 1988 | 125 | 0.000 |
Why?
|
| Pediatrics | 1 | 1997 | 1210 | 0.000 |
Why?
|
| Environmental Exposure | 1 | 1988 | 234 | 0.000 |
Why?
|
| Veins | 1 | 1985 | 101 | 0.000 |
Why?
|
| Necrosis | 1 | 1985 | 210 | 0.000 |
Why?
|
| Arteries | 1 | 1985 | 222 | 0.000 |
Why?
|
| Cerebral Hemorrhage | 1 | 1985 | 158 | 0.000 |
Why?
|
| Genetic Linkage | 1 | 1985 | 475 | 0.000 |
Why?
|
| Transplantation Immunology | 1 | 1983 | 45 | 0.000 |
Why?
|
| Time Factors | 1 | 1988 | 6451 | 0.000 |
Why?
|